We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
- Authors
Nishizawa, Toshihiro; Suzuki, Hidekazu; Nakagawa, Izumi; Iwasaki, Eisuke; Masaoka, Tatsuhiro; Hibi, Toshifumi
- Abstract
Background and Aim: This study was designed to investigate the efficacy of gatifloxacin (GAT)–based triple therapy as a third-line treatment for Helicobacter pylori ( H. pylori) eradication, according to the assessment of the susceptibility to GAT and gyrA mutation. Methods: Fourteen patients who had eradication failure following both clarithromycin-based triple therapy and metronidazole-based triple therapy, or who were infected with H. pylori isolates that were resistant to both clarithromycin and metronidazole after failure of clarithromycin-based triple therapy, were enrolled. These patients were randomly assigned to two groups: (i) rabeprazole and amoxicillin (RA) and (ii) rabeprazole, amoxicillin, and GAT for 7 days (RAG). The minimal inhibitory concentrations were determined by the agar dilution method. The gyrA gene was examined by sequencing. Results: The eradication rate was 0% in the RA group and 75% in the RAG group. The eradication rate in the RAG group was 100% in patients infected with GAT-susceptible bacteria and/or bacteria without gyrA mutations, but was only 33.3% in those infected with GAT-resistant bacteria or bacteria with gyrA mutations. Conclusion: Although GAT may be a promising candidate for third-line therapy, its selection must be based on the results of drug susceptibility testing or gyrA analyses.
- Subjects
HELICOBACTER pylori; TREATMENT of helicobacter pylori infections; GENES; GENETIC mutation; DRUG resistance in microorganisms
- Publication
Journal of Gastroenterology & Hepatology, 2008, Vol 23, pS167
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/j.1440-1746.2008.05407.x